TY  - JOUR

T1  - Efficacy and safety of dupilumab in children aged 6–11 years with inadequately controlled severe atopic dermatitis: Results from an open-label extension trial up to 1 year

JO  - Revue Française d'Allergologie et d'Immunologie Clinique

PY  - 2022/04/01

AU  - Cork MJ

AU  - Guttman-Yassky E

AU  - Simpson EL

AU  - Soong W

AU  - Wang Z

AU  - Chuang CC

AU  - O’malley JT

AU  - Bansal A

ED  - 

DO  - DOI: 10.1016/j.reval.2022.02.078

VL  - 62

IS  - 3

SP  - 321

Y2  - 2024/12/22

ER  -